Overall, this study suggests the use of a small molecule KYA1797K, which destabilizes both Ras and β-catenin, as a novel targeted therapeutic strategy that overcomes the resistance of EGFR TKIs in KRAS mutated NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.